Subject: Participation in survey “Trans-arterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma”
According to the GLOBOCAN 2022 estimates, 38703 new cases of liver cancer were diagnosed in 2022 in India. Hepatocellular carcinoma is the most common type of primary liver cancer (>90%).
There have been significant advances in the therapies for HCC over the past 20 years. The various management strategies include hepatic resection (HR), liver transplantation (LT), locoregional treatments (including percutaneous ablation, trans-arterial chemoembolization [TACE], radioembolization), stereotactic body radiation therapy, and systemic therapies. The selection of a treatment method is based on the number and size of HCC, the status of the portal vein, changes in liver function, and patients’ performance status. Barcelona Clinic Liver Cancer (BCLC) is the most widely used algorithm guiding patient management.
Liver tissue is very sensitive to radiation. The biggest challenge with external beam radiotherapy was that it had to pass through the healthy tissue, causing its destruction. Intraarterial therapy became a solution to this problem. TARE using yttrium-90 microspheres has emerged as an effective and safe treatment option for patients with unresectable metastatic colorectal cancer with liver-dominant metastases and primary liver tumors. Y90 microspheres emit beta radiation within a relatively small radius (mean 2.5 mm), delivering tumoricidal radiation doses to localized regions in the liver while limiting the dose to healthy liver tissue. TARE can be performed with whole-liver treatment, as well as lobar or segmental approaches.
HCC is radiosensitive, radiation therapies have a significant role in its management. Radiation therapies offer local control for unresectable lesions and for patients who are not surgical candidates. Radiotherapy also provides palliation in metastatic disease, and acts as a bridge to resection and transplantation in selected patients.
There is limited data available on patient’s selection criteria for Y90 TARE in HCC management. This multicentric survey is designed to understand the management of mHCC and place of Y90 TARE in HCC management in India.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})